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ORIGINAL ARTICLE

ROLE OF ASSESSMENT FOR RETREATMENT WITH
TRANSARTERIAL CHEMOEMBOLIZATION SCORE IN DECISION OF
RETREATMENT WITH TRANS-ARTERIAL CHEMO-EMBOLIZATION
SESSIONS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Anwar Hussain Abbasi, Shahab Abid, Tanveer ul haq, Safia Awan
Aga khan University Hospital, Karachi-Pakistan

Background: The objective behind this study was to determine that Assessment for Retreatment with Transarterial chemoembolization (ART) score is really applicable in patients
with hepatocellular carcinoma. Methods: A cross sectional observational study was
conducted on all patients with hepatocellular carcinoma of intermediate stage and undergone
≥2 Transarterial chemoembolization. ART score was assessed before and after each session of
Transarterial chemoembolization. Multi-logistic regression analysis was performed to
compare the final outcome of patients with ART score of ≥2.5 into groups with two and more
than two Trans-arterial chemo-embolization sessions. Results: A total of 100 HCC patients
were recruited for final analysis. Our study participants consisted of total 100 HCC patients.
Mean Child Pugh score was 6.1±0.95. In our study, most of the study participants (n=63) had
ART score of less than 1.5 as compared to ART score >2.5 (n=37). A significant proportion
of patients with ART score of <1.5 prior to second Trans-arterial chemo-embolization had
better median survival as compared to patients with ART score of >2.5, p-value<0.001.
Patients with ART score of more than 2.5 did not show any survival benefit after having 3rd
or 4th Trans-arterial chemo-embolization session, p=0.47. Conclusions: Our study findings
suggest that those HCC patients who receive multiple sessions of TACE with a low ART
score have more favourable outcomes with increased survival rate.
Keywords: Hepatocellular carcinoma; Child Pugh Classification; MELD score; ART score
J Ayub Med Coll Abbottabad 2017;29(3):378–83

INTRODUCTION
Hepatitis C virus infection is the single most
common cause of end stage sequelae of chronic
liver disease called hepatocellular carcinoma
(HCC).1 Hepatocellular carcinoma is now the 5th
most common cancer among all worldwide.2
Because of long infective course of HCV infection
majority of the patients with underlying HCC
diagnosed at their 5th or 6th decade of life.3 The
treatment of patients with HCC varies from
medical therapy to surgical procedures. As per
Barcelona Clinic Liver Cancer (BCLC) guidelines
for HCC, various options can be adapted after
assessing
liver
function
and
tumour
characteristics.4–6
Mainly population affected with HCC
present at their advance stage of disease where
treatment -options become limited and only
symptomatic treatment can be offered because
survival of such kind patients not more than 11-20
months.7–8 Those patients who fall under category
of intermediate stage HCC and BCLC stage B
(asymptomatic patients with large or multifocal
HCC and no extrahepatic extension) are treated
with Transarterial chemoembolization (TACE).9–11
On the other hand, TACE can also be used in
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patients who are awaiting for liver transplantation
as a bridging therapy. 12
Most of the previously conducted studies
have determined several factors which may affect
the overall prognosis of TACE such as extent of
liver dysfunction, tumour size and characteristics,
levels of alpha-fetoprotein (AFP), child-pugh
classification, and liver function test. 9–15
If liver function gets worse after taking
TACE sessions so these kinds of patients cannot
take further TACE sessions or any other antitumor
treatment. 9,11,16
Sieghart and his colleagues made a
scoring system named as ART used to predict
survival of HCC patients after having first TACE
session.17 This score can only be calculated using
variables like presence or absence of radiologic
tumour response, increase in Child score or AST
(Aspartate transaminase). The methods used to
calculate ART score is by selecting two separate
groups of patients who do not share similar
prognostic value. The ART score cannot be
accurately calculated in patients who experienced
more than one sessions of TACE.17 Although,
majority of HCC patients who are in intermediate
stage require more than two sessions in a
sequential manner.11,17,18 That is why prognostic
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value of repeated TACE session is scientifically
need to be determine which has not been observed
in our population and very few international
literatures are available. So, this study will be
conducted to determine that ART score is really
applicable in patients with hepatocellular
carcinoma at a tertiary care hospital in Pakistan.

MATERIAL AND METHODS
This cross-sectional hospital based study was
conducted at Aga Khan University, Karachi for a
period of fourteen years (January 2001 to 31st
December 2014) in all patients admitted in a
gastroenterology unit for TACE procedure through
a consecutive sampling technique.
All diagnosed admitted cases of HCC with
age more than 18 years of either gender treated
with more than two sessions of TACE (time
between the TACE cycles each >90 days) and fall
under BCLC category of stage A or B along with
preserved liver functions (Child-Pugh class A or
B) were enrolled under this study. The diagnosis of
HCC was made using guideline based diagnostic
criteria by European Association for the Study of
the Liver Disease (EASL).5
Patients who were in child class C or
BCLC stage C and those patients who received
TACE prior to orthotopic liver transplantation
(OLT) or resection, or if patient received TACE
for HCC recurrence after OLT were excluded from
the study. The study approved by the ethical
review committee of Aga Khan University
Hospital (ERC #3458-Med-ERC-15)
We have documented any adverse event that
occurred within 30 days of any TACE session
The ART score has three variables (Table-1).
Table-1: Art score
ART score Points
Radiologic tumour response
Absent 1
Present 0
AST increase > 25%
Present 4
Absent 0
Child-Pugh score increase
1 point 1.5
≥ 2 points 3
Absent 0

The ART score is calculated on the basis of sum of
all three variables. As we have divided the patients
into two groups based on their ART score as <1.5
and more than 2.5, the cut off value was set
accordingly to determine the survival among these
patients.
All data entered and analysed by using the
Statistical package for social science SPSS

(Release 16.0 and a p-value <0.05 were considered
as statistically significant.
Quantitative variables were presented as
means and SD such as age, AFP, child score, and
MELD (Model for end stage liver disease) score
and number (Percentage) for qualitative variables,
such as gender and aetiology of cirrhosis. In our
study, the survival of patients was calculated from
the day of first ART score assessment until the
patient died or till last visit. Those who lost
follow-up were excluded from the study. Kaplan
Meier analysis was performed to measure the inhospital outcome in months. Multi-logistic
regression analysis was performed to observe the
effect of multiple variables on survival.

RESULTS
A total of 790 patients had TACE between January
2001 to December 2014. Two hundred fifty-six
patients had ≥2 TACE sessions, 156 patients excluded
due to missing variables. Total of 100 patients were
included in the final analysis (Figure-1).
Out of 100 patients, 51 patients underwent 3 TACE
sessions and 19 patients underwent 4 TACE sessions.
Tumour response was present in 14 patients.
Decompensation after TACE was seen in 15 patients,
most common decompensation was ascites (14/15
patients). AST rise was seen in 23 patients after
TACE. During follow-up period of average 48 months
(range 20-74 months); overall mortality rate was
observed out of 100 patients was 80% (n=80). A
median of 27 months was observed as overall survival
of patients in our study (95% CI, 11.4–32.7 months).
The survival was calculated when the date patent was
enrolled till his/her death. A significant association
was observed in a univariate analysis among patients
who underwent 1st TACE with 2nd, 3rd and 4th TACE
after 27 vs. 25 vs. 12 months, p value 0.01 (Table-3).
On multivariate analysis, child class and ART score
had prognostic significance (Table-4)
Overall, patients with an ART score of 0–
1.5points (n=63) before TACE-2 had a median
survival of 29 months [95% CI: 26.21-31.78] vs. those
with some of ≥ 2.5 points (n=37) median survival
25months
[95%CI:
11.10-22.89]
p-value
<0.001(Figure-2). Before TACE-3 and TACE-4 same
results obtained (Figure-3,4). When a subgroup
analysis was done in these patients, whether they had 2
TACE sessions or more than 2 TACE sessions, it was
observed that there was no survival difference between
both groups [18 months vs. 21 months, p value 0.47]
(Figure-5).
There was no survival difference in patients with HCC
size <5cm vs. >5cm (Figure-6) or AFP level <200 vs.
>200 iu/ml (Figure-7).
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Table-2: Baseline characteristics of study patients (n=100)
Characteristics
Mean+SD/ %
Age, in years (Mean and SD)
57.53±9.8
Male
82
Female
18
Child score (Mean and SD)
6.1±0.95
Child class
A
71
B
29
Aetiology of cirrhosis
HCV
67
HBV
17
NBNC
11
HBV+HCV
3
BCS
1
ALD
1
Tumour size
<5cm
62
>5cm
38

Characteristics
MEAN +SD/ %
MELD score (mean and SD)
9.4±2.3
Tumour size <5cm
62
Tumour size >5 cm
62
BCLC stage
A
61
B
39
∞- Fetoprotein
<200
65
≥200
35
Tumour response present
14
Decompensating after TACE
15
AST >25%
23
Before TACE 2
Child score
6.5 ± 1.05
Before TACE 3
Child score
6.4 ± 0.87
Before TACE 4
Child score
6.3 ± 1.12

Table-3: Univariate analysis of prognostic factors
Variable
Age
<65 years
≥65
Aetiology
Viral
others
∞- Fetoprotein
<200
≥200
Tumour size
<5 cm
>5 cm
BCLC stage
A
B
AST >25%
No
Yes
Tumour response
No
Yes
Child score increase
0 points
1 points
≥2 points

n=100

Median

95% CI

p value

64
36

64
36

20.06–27.93
23.92–36.08

0.27

87
13

27
21

23.8–30.11
13.07–28.92

0.65

65
35

27
22

21.38–32.61
17.87–26.12

0.23

62
38

27
25

20.66–33.33
19.44-30.56

0.31

61
39

25
25

18.81–31.19
19.34–30.65

0.37

84
16

27
14

23.91–30.08
6.51–21.48

0.19

88
12

25
28

20.07–29.92
24.91–31.08

0.70

66
27
7

27
25
12

23.20–30.79
11.40–38.60
10.71–13.28

0.01

Table-4: Multivariable cox regression of prognostic factors
Variable
Child stage
A
B
ART score
0-1.5 points
≥2.5 points
AST >25%
No
Yes
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Hazard Ratio

95% CI

p value

1.0
3.19

1.58–6.44

0.001

1.0
2.56

1.17–5.59

0.01

1.0
0.37

0.16-1.33

0.12
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790 patients has
TACE b/w Jan 2001
to December 2014

256 patients had ≥
2 TACE sessions

156 excluded due
to missing
variables

100 patients
completed the
protocol

51 patients had 3
TACE sessions

19 patients had 4
TACE sessions

Figure-1: Flow diagram

Figure-2: ART score before TACE 2

Figure-4: ART score before TACE 4

0-1.5 points (n=63): Median survival time: 29months [95% CI:
26.21-31.78], ≥2.5 points (n=37): Median survival time: 25months
[95%CI: 11.10–22.89] p value <0.001

0–1.5 points (n=10): Median survival time: 43months [95% CI:
29.77–56.22], ≥2.5 points (n=9): Median survival time: 30months
[95% CI: 23.54-36.54] p value= 0.1

Figure-3: ART score before TACE 3

Figure-5: Sub-group analysis of patients with
ART score >2.5

0-1.5 points (n=32): Median survival time: 32months [95% CI:
27.39–36.60], ≥2.5 points (n=19): Median survival time: 25months
[95%CI: 16.46–33.53] p value= 0.02

2 TACE (n=27): Median survival time: 18 months [95% CI: 9.9120.08], >2 TACE (n=10): Median survival time: 21 months [95%
CI: 1–50.44] p value=0.47
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Figure-6: Survival difference between HCC
patients with tumour size <5cm vs >5cm
<5 cm (n=62): Median survival = 27 months [20.66-33.33],n >5cm
(n=38): Median survival = 25 months [19.44-30.56] p value=0.31

In patients with a dismal ART score (≥2.5 points)
prior to TACE-2, when we did subgroup analysis, we
found that there is no survival benefit between
patients who had only two TACE sessions or more
than two TACE sessions (survival 18-month vs 21
months, p value 0.47). If we find ART score (≥2.5
points), then these patients should not be subjected to
further TACE sessions and should be offered other
treatment options like systemic therapy with
sorafenib etc.19,20
Few limitations of the study include
retrospective study design, missing variables of the
patients with ≥2 TACE sessions so ART score before
TACE 2 only be calculated in 100 patients. Still
sample size was adequate to compare the groups with
high and low ART score.

CONCLUSION
Our study findings suggest that those HCC patients
who receive multiple sessions of TACE with a low
ART score have more favourable outcomes with
increased survival rate.
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Figure-7: Survival difference between HCC
patients with AFP <200 vs AFP >200
<200 (n=65) = Median survival = 27 months [21.38-32.61], >200
(n=35) = Median survival = 22 months [17.87-26.12] p value=0.23
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